Mortality of all causes and sudden unexplained death in epilepsy (SUDEP) in a cohort of 235 persons living with epilepsy in Rwanda using WHO Verbal Autopsy Questionnaire

Fidèle Sebera, Béné H. Uwacu, Wellars Nsanzabaganwa, Josiane Umwiringira, Peter Dedeken, Dirk E. Teuwen, Paul A.J.M. Boon

INTRODUCTION

Mortality in persons living with epilepsy (PwE) is 1.6–9.3-fold higher than in the general population. Mortality from definite/probable Sudden Unexpected Death in Epilepsy (SUDEP) is estimated at 1.2 per 1000 person-years. We report mortality and SUDEP rate in a cohort of Rwandan PwE.

METHODS: PwE presenting for a first visit at the Ndera epilepsy center between January and June 2016 were followed-up prospectively. For PwE who did not attend their follow-up visit, home visits were organized. Deaths were assessed using World Health Organization Verbal Autopsy Standards age-specific questionnaires.

RESULTS: Of 235 PwE enrolled, home visits were organized for 81 (34.4%) PwE who did not return for their follow-up consultation. Seven fatalities (mortality 16.7/1000 patient-years [CI 6.7–34.3]) were recorded (aged 2–80 years). Four had an identified cause. Three were classified as probable SUDEP, resulting in a probable SUDEP rate of 7.1/1000 patient-years (CI 1.47–20.86). Probable SUDEP occurred in PwE (age: 2, 21, 34 years) showing no symptoms of illness while receiving antiepileptic treatment; in two cases, death occurred during sleep.

CONCLUSION: Although autopsies were absent, the high mortality and probable SUDEP rates warrant future studies to establish causes of epilepsy-related deaths in Rwanda and sub-Saharan Africa.

© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
age) [6,8]. Mortality and SUDEP rates in SSA and other LLMIC remain unclear. Definite SUDEP is considered when diagnostic criteria are met and when no other cause of death has been identified through an autopsy or immediate observation surveillance. As autopsies in SSA are very rarely performed, SUDEP is often only reported as probable or possible.

In this report, we describe all-cause mortality and probable SUDEP cases prospectively studied in a cohort of PwE in Rwanda, using the age-specific World Health Organization (WHO) Verbal Autopsy Questionnaire. This tool was designed and validated to assess cause(s) of mortality in the absence of autopsies, which is frequent in LLMIC. The structured questionnaire guides the interviewer during the visit, covering different causes of death and allows additional data from death certificates at town halls or medical files, if available [9].

2. Materials and methods

Between January and June 2016, PwE presenting at the CARAES Neuropsychiatric tertiary hospital (CARAES-NPH) at Ndera (Kigali, Rwanda) were enrolled into an ambispective cohort study only if they presented at the clinic for the first time and had a first seizure or an epilepsy diagnosis of <12 months. Epilepsy was defined as a history of two or more unprovoked seizures [10]. Survival status was assessed by a physical presentation at an out-patient consultation. If a PwE had not returned (lost for follow-up), a home visit was organized to assess the PwE health status.

A multidisciplinary team, including a neurologist, nurse, and research assistant, visited PwE and family at their last known address. Upon verbal consent, the survey, approved by the Ethical Review Board of the CARAES-NPH and Institutional Review Board of the University Teaching Hospital – Kigali (CHU-K), was administered. Survival status verification was completed at 19 months after the enrollment.

When family members reported the death of a PwE, another home visit was conducted. The team interviewed family and/or caregivers using the age-specific World Health Organization (WHO) Verbal Autopsy Questionnaire age-specific questionnaire [9].

2.1. Classification of epilepsy-related deaths

We used the 2016 classification of epilepsy-related deaths with four categories: (i) deaths due directly to epilepsy, including SUDEP; (ii) deaths due indirectly to epilepsy; (iii) deaths due to acute symptomatic seizures; and, (iv) deaths due to underlying disease [7].

2.2. Criteria and classification of SUDEP

The SUDEP criteria used were: (i) the deceased, before death, had to have had repetitive unprovoked epileptic seizures; (ii) death had to have occurred unexpectedly, i.e., in an everyday situation and in people with an otherwise unremarkable state of health; (iii) death had to have occurred suddenly, i.e., within minutes (if observed); and (iv) there had to be no evidence of any other cause of death, e.g., trauma, drowning, status epilepticus, burns, or accident [11,12].

Six categories of SUDEP were considered: (i) definite SUDEP if diagnostic criteria were met without evidence of another cause of death through an autopsy or immediate observation surveillance; (ii) probable SUDEP if any or all of the criteria described above were met in the absence of an autopsy; (iii) possible SUDEP if a competing cause of death was present; (iv) near-SUDEP when a PwE had a resuscitation after a respiratory and cardiovascular arrest for which no other cause was found, with the person surviving for up to 1 h; (v) no SUDEP if a clear cause of death was known; and, (vi) unclassifiable SUDEP when incomplete information did not allow classification [11,12].

3. Results

A total of 235 PwE were followed up prospectively. Based on the medical records, at 19 months after inclusion, attempts to PwE by phone were made and included 81 (34.5%) PwE who did not return for a follow-up consultation. Of these 81 PwE, seven PwE had moved abroad and 74 home visits were organized. Seven PwE could not be traced at their last known address and authorities did not know their new address. The team completed home visits of these PwE and family members of seven deceased PwE.

Out of 35 reasons for loss to follow-up, most frequently reasons cited were lack of insurance/financial means (25.7%), seizure cessation (25.7%), lack of improvement (25.7%) and lack of information/having a normal EEG (14.3%).

At study enrollment, 56% of 235 PwE were male and 70% were <20 years of age (mean 15.6 years, range 0–78 years). Focal-onset including focal to bilateral tonic–clonic seizures (TCS) were present in 12.6% of PwE, whereas unclassified seizures had occurred in 6%. Another 79.4% presented with TCS with unknown onset (and may have included generalized and focal onset seizures), because of limited electroencephalogram and a monthly seizure frequency >10 was reported in 19.6%. Mean age at first seizure and at clinical diagnosis was 10.8 years and 13.4 years, respectively [13].

Clinical features and details of the seven death cases are described in Tables 1 and 2. At baseline, five of seven deaths recorded were male (71.4%), mean age was 31.4 years (range 1–78 years), and six of seven (85.7%) had unknown onset TCS. Three PwE had more than 10 seizures per month and two had less than two seizures per month.

Based on a total of 420.3 person-years in our cohort, mortality was 16.7 per 1000 person-years (CI 6.7–34.3) conservatively excluding seven PwE who could not be contacted and assumed alive. Four deaths were attributed to specific causes: brain tumor, metastatic liver cancer, head trauma secondary to a seizure, and hypovolemic shock. Of six PwE with known time of first seizure, four had an epilepsy duration of less than five years.

Three cases on AED treatment were classified as probable SUDEP in the absence of trauma or concurrent illness at time of death. The SUDEP rate in this cohort was estimated to be 7.1 per 1000 person-years (CI 1.5–20.9). At the last documented consultation, two of three PwE who had probable SUDEP were seizure-free for 3 months after respectively presenting with between two and five seizures and >10 seizures per month initially. In two SUDEP cases, death occurred during sleep.

4. Discussion

This study reported all-causes mortality and SUDEP rates of a selected PwE population seen at a tertiary referral center [5,6]. Mortality in our cohort was lower than that reported in data from Kenya showing a mortality of 33 per 1000 person-years [14]. In countries with a large epilepsy diagnosis and treatment gap (DTG), epilepsy has an increased incidence of premature mortality [15]. The DTG may increase mortality from all causes, including deaths attributable to lack of access to medical facilities for diagnosis and treatment, e.g., status epilepticus, or preventable causes, e.g., accidents, drowning, head traumas, and burns [15]. In our cohort, the treatment gap may have contributed to mortality as only one death case was on dual treatment and only two PwE were reported seizure-free. Moreover, death registries are often lacking and autopsies not performed; hence, accurate estimation of the occurrence of epilepsy-related mortality in LLMIC can be significantly hampered [16].

The multidisciplinary team proactively organized home visits and interviewed family members and/or caregivers using the validated WHO Verbal Autopsy Questionnaire to understand cause(s) of death, to mitigate for the lack of death or epilepsy registries [9,16].

According to the 2016 classification, four deaths (57.1%) were considered directly attributable to epilepsy (three instances of probable SUDEP and one secondary to head trauma following a seizure); two
Demographics and seizure details of PwE with reported death.

| Patient | Gender | Age (years) | Seizure Onset | Seizure frequency | Technical investigations | Medication |
|---------|--------|-------------|--------------|-------------------|--------------------------|------------|
|         |        |             | Seizure Classification | At inclusion | At last OPD visit | At death reported by family | EEG | CT/MRI | AED | Concomitant |
| 1       | Male   | 38          | Unknown onset, tonic–clonic seizures | <2/mo | <2/mo | Partial seizure control | Normal | No | Carbamazepine | None |
| 2       | Female | 10          | Unknown onset, tonic–clonic seizures | 10–30/mo | <2/mo | Partial seizure control | Abnormal\(^{a}\) | No | Valproic acid, phenobarbital | None |
| 3       | Male   | 25          | Unknown onset, tonic–clonic seizures | 2–5/mo | 3 mo seizure-free | Seizure-free | Unknown | No | Carbamazepine | Haloperidol |
| 4       | Male   | 36          | Focal to bilateral seizures | <2/mo | <2/mo | Unknown | Normal | No | Valproic acid | Amitriptyline |
| 5       | Female | 0           | Unknown onset, tonic–clonic seizures | 10–30/mo | 10–30/mo | Partial seizure control | Abnormal\(^{a}\) | No | Valproic acid | None |
| 6       | Male   | UNK 78      | Unknown onset, tonic–clonic seizures | 5–10/mo | 5–10/mo | Partial seizure control | Unknown | Unknown | Phenobarbital | None |
| 7       | Male   | 0 2 2.9     | Focal to bilateral seizures | 10–30/mo | 10–30/mo | Seizure-free | Abnormal\(^{a}\) | No | Valproic acid | None |

AED = antiepileptic drug; CT/MRI = brain computed tomography/magnetic resonance imaging; DoB = date of birth; EEG = electroencephalogram; OPD = outpatient department; UNK, unknown.

\(^{a}\) Excess delta/theta waves, without epileptic activities.

\(^{b}\) Theta waves.

\(^{c}\) Severe encephalopathy.

(28.6%) were the result of underlying neurological disease, and one (14.3%) was related indirectly to epilepsy [5,7,11,12]. The proportion of probable SUDEP of 3/7 (43%) was higher than in the Kenyan cohort (about 7%), which may be due to population differences or to the home visits we conducted [14]. The diagnosis of SUDEP remains difficult in high-income countries and is even more complex and unlikely to be recorded in LLMIC. Risk factors for SUDEP include TCS, high frequency of seizures, nocturnal seizures, polytherapy, non-compliance, age <45 years, and long duration of the condition [17]. In our cohort, the SUDEP risk factors of age <45 years and TCS were present in all cases, and two PwE had a time since seizure onset of more than nine years. In children, brain lesions, male gender, and cognitive or developmental delay are considered additional risk factors [5]. A delayed mental development was observed in the two toddler SUDEP cases. Having gathered data on mortality and SUDEP cases, the reported rates need to be interpreted with caution as the study (i) was not specifically designed as a mortality study; (ii) had a relatively short follow-up period; and, (iii) potentially selected a population with

Table 2

Narrative and suspected cases of death in seven PwE by using the WHO Verbal Autopsy.

| Patient | Health status | Description | Sleep/awake | Infection | GI disease | Cardiac disease | Lung disease | WHO diagnosis |
|---------|---------------|-------------|-------------|-----------|------------|----------------|--------------|---------------|
| 1       | Active life   | The person was apparently fine, reading at home. At around 03:00 pm, he went outside, had a seizure, fell on one leg, and took some steps, and suffered head trauma. He went to bed, but was later discovered unconscious by family members | Awake | No | No | No | No | Head trauma, secondary to seizure |
| 2       | Active life   | At around 03:00 am, the person called out to her mother explaining that she did not feel well. She displayed no signs of fever, pain, or other illness. Having returned to bed to sleep, she passed away during the night. | Asleep | No | No | No | No | Probable SUDEP |
| 3       | Active life   | At around 03:00 pm, while conducting business, the person told his business partner that he did not feel well. He displayed no signs of fever, pain, depression, paranoid schizophrenia, or other illness. He went home to rest, but after 1 h, his business partner discovered him dead at his home, without apparent injuries. | Asleep | No | No | No | No | Probable SUDEP |
| 4       | Deterioring health | The person, previously diagnosed with a brain tumor, was admitted to the emergency department of CHU-K in a comatose state. He received palliative care but died 5 days later. | Coma | No | No | No | No | Brain tumor |
| 5       | Delayed mental development | The medical history of the girl included recurrent infections, requiring nasogastric tube feeding, and supportive care. At time of death, the patient was again admitted with diarrhea, unable to take oral hydration. She died of a hypovolemic shock despite rehydration with intra-venous fluids. | Awake | No | Diarrhea | No | Respiratory problems | Hypovolemic shock/dehydration |
| 6       | Deterioring health | The person had known lung cancer. His health status deteriorated steadily with a severe cough, chest and abdominal pain, and weight loss. He died in hospital. | Awake | Fever | Abdominal pain | No | Severe cough | Metastatic lung cancer |
| 7       | Delayed mental development | The boy with known perinatal asphyxia was apparently fine and did not have seizures at the time of his death. He showed no signs of any illness. At around 11:00 am, he was unable to eat and stopped breathing soon afterwards. No convulsions were observed by household members. | Awake | No | No | No | No | Probable SUDEP |

CHU-K = University Teaching Hospital – Kigali; GI = gastrointestinal disease; PwE = person with epilepsy; SUDEP = Sudden Unexplained Death in Epilepsy; WHO = World Health Organization.
likely more severe epilepsy having been referred by district hospital levels. This may have resulted in an overestimation of actual rates compared to the general PwE population as only recently diagnosed PwE were recruited at the tertiary reference center. Similar to other LLMIC, further limitations to assess causes of mortality including SUDEP were an absence of autopsies and limited access to neuroimaging, most likely underestimating brain lesion-related epilepsy [14].

Given these limitations, the WHO Verbal Autopsy Questionnaire was a useful tool for assessing the cause of mortality in a structured and systematic way. We recommend its future use in all instances of deaths of PwE.

Research is ongoing and more is required to improve our understanding of both epilepsy-related mortality and SUDEP rate in Rwanda, and to a broader extent, in SSA.

Ethical statement

The authors confirm that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, and is in line with the Recommendations for the Conduct, Reporting, and Publication of Scholarly Work in Medical journals. Where applicable, informed consent from human participants and approval from the appropriate ethical review boards were obtained, as described in the manuscript.

Acknowledgments

The team is grateful to family members and caregivers of the deceased for providing their informed consent for participation in this study. The authors acknowledge the contribution of Fabien Debailleul, PhD (UCB Pharma, Brussels, Belgium) for managing the development of the manuscript, and Leonard Wills (Evidence Scientific Solutions, London, UK) for editorial assistance, which was funded by UCB Pharma.

Declaration of competing interest

D. Teuwen is an employee of UCB Pharma. P. Dedeken received consultancy fees from UCB Pharma and Novartis. P. Boon received speaker and consultancy fees from UCB Pharma, LivaNova, and Medtronic, and research grants from the same companies through his institution. The other authors have no interests to declare.

Funding disclosure statement

This study was supported with an unrestricted educational grant from UCB Pharma. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. F. Sebera received study funding through the Ndera CARAES Neuropsychiatric Hospital Research Department.

Data statement

Data from non-interventional studies is outside of UCB’s data sharing policy and is unavailable for sharing.

References

[1] Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010; 51(5):883–90. https://doi.org/10.1111/j.1528-1167.2009.02481.x.
[2] GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357–75. https://doi.org/10.1016/S1474-4422(18)30454-x.
[3] Owolabi LF, Adamu B, Jibio AM, Owolabi SD, Isa AI, Alhaji ID, et al. Prevalence of active epilepsy, lifetime epilepsy prevalence, and burden of epilepsy in sub-Saharan Africa from meta-analysis of door-to-door population-based surveys. Epilepsy Behav. 2020;103(Pt A):168846. https://doi.org/10.1016/j.yebeh.2019.106846.
[4] Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990-2017: results from the Global Burden of Disease Study 2017. Lancet Glob Health. 2019;7(10):e1375–87. https://doi.org/10.1016/S2214-109X(19)30374-2.
[5] Mbizvo GK, Bennett K, Simpson CR, Duncan SE, Chin RIM. Epilepsy-related and other causes of mortality in people with epilepsy: a systematic review of systematic reviews. Epilepsy Res. 2019;157:106192. https://doi.org/10.1016/j.eplepsyres.2019.106192.
[6] Sveinsson O, Andersson T, Carlsson S, Tomson T. The incidence of SUDEP: a worldwide population-based cohort study. Neurology. 2017;89(2):170–7. https://doi.org/10.1212/WNL.0000000000004054.
[7] Devinsky O, Spruill T, Thurman D, Friedman D. Recognizing and preventing epilepsy-related mortality: a call for action. Neurology. 2016;86(8):779–86. https://doi.org/10.1212/WNL.0000000000002253.
[8] Keller AE, Whitney R, Li S-A, Pollanen MS, Donner EJ. Incidence of sudden unexpected death in epilepsy in children is similar to adults. Neurology. 2018;91(2):e107–11. https://doi.org/10.1212/WNL.0000000000005762.
[9] World Health Organization. The 2016 WHO Verbal Autopsy Instrument. http://www.who.int/healthinfo/statistics/verbalautopsystandards/en/. [Accessed 1 June 2017].
[10] Fisher RS, Cross JJ, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522–30. https://doi.org/10.1111/epi.13670.
[11] Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definition of sudden unexpected death in epilepsy. Epilepsia. 2012;53(2):227–33. https://doi.org/10.1111/j.1528-1167.2011.03558.x.
[12] May TW, Israel CW. Sudden unexpected death in epilepsy (SUDEP): epidemiology, cardiac and other risk factors [article in German]. Herzschrittmacherther. Elektrophysiol. 2019;30(3):274–86.
[13] Van Steenikste F, Sebera F, Nsambaabagwana W, Uwacu P, Dedeken P, Teuwen DE, et al. An ambispective cohort study on treatment outcomes of patients with epilepsy in a tertiary epilepsy center in Rwanda and recommendations for improved epilepsy care. Epilepsia Open. 2019;4(1):123–32. https://doi.org/10.1002/epio4.12304.
[14] Ngugi AK, Bottomley C, Fegan G, Chengo E, Odhiambo R, Bauni E, et al. Premature mortality in active convulsive epilepsy in rural Kenya: causes and associated factors. Neurology. 2014;82(7):582–9. https://doi.org/10.1212/WMN.0000000000000123.
[15] Levi F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H, et al. Premature mortality of epilepsy in low- and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58(1):6–16. https://doi.org/10.1111/epi.13603.
[16] Pickrell WD, Kerr MP. SUDEP and mortality in epilepsy: the role of routinely collected healthcare data, registries, and health inequalities. Epilepsy Behav. 2020;103(Pt B):106453. https://doi.org/10.1016/j.yebeh.2019.106453.
[17] Harden C, Tomson T, Gloss D, Buchhalter J, Cross JJ, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88(17):1674–80. https://doi.org/10.1212/WNL.000000000003685.